Allergy Testing Access Act of 2021
Latest action (11 Mar 2021): Introduced
What this bill does
Generate a neutral, plain-English explanation of what this bill does, who it affects and what happens next — grounded in the official text.
Official summary
Allergy Testing Access Act of 2021
This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare.
Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.
Common questions
- What does S. 701 do?
- Allergy Testing Access Act of 2021 This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare. Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.
- Has S. 701 become law?
- Not yet. As of 11 Mar 2021, S. 701 is introduced.
- Who sponsored S. 701?
- S. 701 was sponsored by Sen. Jerry Moran [R-KS] (Republican-KS), with 7 cosponsors.
- What's the latest action on S. 701?
- Introduced (11 Mar 2021).
Related bills in Health
Recognizing the importance of protecting continuous Medicaid coverage for individuals undergoing active cancer treatment.
Wildland Firefighter Health and Safety Act
A resolution supporting the designation of October 2026 as “Substance Use & Misuse Prevention Month” to raise awareness of substance use and misuse in the United States.
Expressing support for the designation of the third week of September as “Fungal Disease Awareness Week” and encouraging efforts to improve awareness, diagnosis, treatment, surveillance, and prevention of fungal diseases in the United States.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.